Lv3
260 积分 2023-05-03 加入
Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
1个月前
已完结
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
1个月前
已完结
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
3个月前
已完结
An Antibody–Oligonucleotide Conjugate for Myotonic Dystrophy Type 1
4个月前
已完结
Molecular mechanisms underlying nucleotide repeat expansion disorders
6个月前
已完结
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
7个月前
已完结
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy
8个月前
已完结
† VERVE-102, a clinical stage in vivo base editing medicine, leads to potent and precise inactivation of PCSK9 in preclinical studies
9个月前
已完结
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy
9个月前
已完结
To the Editor—Impact of mavacamten on atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy
9个月前
已完结
皖公网安备34019202002308
